Is Genetic Testing Worth It? Pros, Cons & Costs

Genetic testing is worth it for many people, but the answer depends heavily on what kind of test you’re getting and why. A clinical test ordered by your doctor to diagnose a rare disease or screen for hereditary cancer risk is supported by strong evidence of real health benefits. A direct-to-consumer kit bought out of curiosity carries a much higher false-positive rate and can create confusion without clear medical payoff. The costs range from under $100 for some consumer tests to several thousand dollars for comprehensive clinical sequencing, with insurance increasingly covering medically indicated tests. The honest picture is that genetic testing is not one thing, and treating it as a single yes-or-no decision misses the point.

Diagnosing Rare Diseases in Children

One of the strongest cases for genetic testing is in children with unexplained developmental, neurological, or multi-organ conditions. These families often endure years of specialist visits and inconclusive workups before anyone suggests looking at the genome. When clinicians do order broad sequencing, it works more often than people expect. A meta-analysis of pediatric rare-disease studies found that genome-wide sequencing produced a diagnosis about 34% of the time, compared with roughly 18% for older, more targeted genetic tests. That meant kids who got the broader test had more than twice the odds of finally getting an answer.

Individual studies land in a similar range. A Czech study of 58 children with rare or undiagnosed conditions found disease-causing variants in 43% of them.¹ A larger cohort of 825 patients reported a diagnostic yield of about 34%, with higher success rates for patients whose conditions affected multiple organ systems.² Getting a diagnosis does not always mean a cure exists, but it ends a diagnostic odyssey, connects families to the right specialists and support communities, and can identify treatments or management strategies that would not have been tried otherwise.

Hereditary Cancer Screening

Testing for inherited cancer risk is where genetic testing has made the most visible difference in clinical practice. Genes like BRCA1 and BRCA2 for breast and ovarian cancer, and the mismatch-repair genes linked to Lynch syndrome, are well-studied enough that finding a harmful variant leads to concrete changes in how you’re monitored and treated. A study of patients who tested positive on multi-gene cancer panels found that for more than half of them, the result led to additional screening or prevention measures beyond what their personal and family history alone would have prompted. Testing also opened the door to evaluating close relatives: among those with first-degree relatives available for follow-up, about 72% would be considered for additional family testing.³

Multi-gene panels, which test for many cancer-related genes at once rather than one or two, have revealed a subtler benefit: they catch diagnoses that narrower testing would miss. In a large cohort of over 165,000 high-risk patients, about 20% of those carrying Lynch syndrome mutations met testing criteria only for BRCA genes. Had their doctors ordered BRCA-only testing, hundreds of Lynch syndrome diagnoses would have gone undetected, and those patients would have missed out on interventions known to reduce their cancer risk and mortality.⁴

Carrier Screening for Family Planning

Carrier screening is aimed at couples who want to know whether they share a risk of passing on a serious genetic condition to a child. Conditions like cystic fibrosis, sickle cell disease, and spinal muscular atrophy are recessive, meaning both parents have to carry a variant for a child to be affected. Expanded carrier screening panels now test for dozens or even hundreds of conditions at once, and the evidence shows that couples act on the results.

Among couples identified as at-risk who were screened before pregnancy, about 77% planned or pursued steps to reduce the chance of having an affected child. Those steps included IVF with embryo testing, prenatal diagnostic testing, use of a donor egg or sperm, and in some cases deciding not to pursue pregnancy at all. For couples already pregnant when results came back, about 37% opted for prenatal diagnostic testing such as amniocentesis.⁵ The severity of the condition mattered: couples facing a risk of profound disease were most likely to pursue testing during pregnancy, and the association between disease severity and decision-making was statistically significant.⁶

This is an area where timing matters a lot. Getting carrier screening before pregnancy gives you the widest range of options. Getting it during pregnancy still allows prenatal diagnosis but narrows what you can do with the information. If you’re planning a family and have any reason to think a genetic condition runs in either partner’s family, this is one of the clearest use cases for genetic testing.

Matching Medications to Your Genes

Pharmacogenomic testing looks at how your genetic makeup affects the way you metabolize and respond to specific drugs. The idea is straightforward: if your genes make you a poor metabolizer of a given antidepressant, prescribing that drug first wastes time and produces side effects that could have been avoided. The most developed clinical evidence for this is in psychiatry, where depression treatment is notoriously trial-and-error.

Results are mixed but trending positive. A large randomized trial (the PRIME Care trial) found that giving doctors pharmacogenomic results reduced prescriptions of drugs with predicted gene-drug conflicts, though the improvement in symptom remission was small and did not persist long-term.⁷ A separate randomized trial showed more encouraging numbers: at eight weeks, the pharmacogenomic-guided group had a remission rate of 24% compared with 15% in the control group, and by twelve weeks the guided group’s advantage held, with less frequent side effects as well.⁸

Beyond psychiatry, a review of preemptive pharmacogenomic testing across multiple drug classes found that patients who received testing had roughly a third lower risk of adverse drug reactions compared with standard care.⁹ Pharmacogenomics is not yet routine for most prescriptions, but if you’re starting a medication known to have strong genetic interactions, like certain blood thinners, antidepressants, or chemotherapy agents, testing beforehand can genuinely improve outcomes.

What Direct-to-Consumer Tests Actually Deliver

Consumer genetic tests from companies you can order online without a doctor occupy a very different space from clinical testing. They’re cheap, accessible, and fun for exploring ancestry. For health-related results, though, the accuracy gap is significant. An analysis of variants reported in direct-to-consumer raw data found that roughly 40% of variants flagged as clinically relevant were false positives when checked by a clinical laboratory. Some variants labeled as “increased risk” turned out to be common, benign variants found throughout the general population.¹⁰

The practical takeaway is that a health result from a consumer test should never be treated as a medical diagnosis. If a consumer test flags something concerning, the next step is confirmatory testing through a clinical lab, ideally with a genetic counselor involved. Acting on unconfirmed consumer results, whether by starting medications, pursuing surgery consultations, or spiraling into anxiety, can cause real harm.

Consumer testing also surfaces information people did not expect or want. A growing body of research documents the experience of people who discover through DNA tests that a parent is not biologically related to them. These non-paternity discoveries are linked to increased levels of depression, anxiety, and panic symptoms.¹¹ The emotional fallout extends beyond the person tested, affecting family trust and relationships in ways that can take years to resolve.¹² People often struggle with whether and how to tell family members, navigating feelings of betrayal, stigma, and uncertainty about consequences.¹³ None of this means consumer testing is bad, but it does mean the “just for fun” framing undersells what you might actually learn.

What Testing Costs and Who Pays

The sticker price of genetic testing ranges widely. Consumer ancestry kits run $100 to $200. A targeted clinical test for one or two genes might cost a few hundred dollars. Whole-exome or whole-genome sequencing, the most comprehensive clinical options, can run from $1,000 to over $5,000 at list price, though prices have dropped sharply over the past decade. The more relevant question for most people is not the sticker price but what they’ll actually pay out of pocket.

Insurance coverage has improved but remains uneven. When testing is ordered by a doctor and meets specific clinical criteria, such as a strong family history of cancer or a child with a suspected genetic condition, most private insurers and Medicaid programs cover it. But full coverage is not always available, and patients who don’t meet strict criteria sometimes face the choice of paying out of pocket or going without.¹⁴ Genetic counselors report that insurance is more likely to cover the testing itself than the counseling that goes with it, and patients are generally more willing to pay for testing than for the counseling session.¹⁵ That’s unfortunate, because counseling is often what makes the test results useful rather than confusing.

From a health-system perspective, population-wide genomic screening is looking increasingly cost-effective, at least for younger adults. A cost-effectiveness analysis estimated that screening 100,000 unselected 30-year-olds for three well-established hereditary conditions would prevent about 101 cancer cases and 15 cardiovascular events, at a cost of roughly $68,600 per quality-adjusted life-year gained, which falls well within the threshold most health economists consider worthwhile.¹⁶ Another analysis focused on breast and ovarian cancer genes found that population-based multigene testing was more cost-effective than the current approach of testing only women with a strong family history, and would prevent an additional 1,338 breast cancers and 663 ovarian cancers per million women screened.¹⁷ The economics get weaker as the population screened gets older, which makes intuitive sense: you get more life-years of prevention from catching something at age 30 than at age 50.

The Psychological Question

One of the biggest worries people have about genetic testing is that the results will be emotionally devastating. The research is reassuring on this point. A meta-analysis across seven major clinical sequencing studies found no significant increase in anxiety or depression after people received their results. If anything, there was a slight trend toward decreased anxiety after disclosure, probably because uncertainty is its own source of stress.¹⁸ A randomized trial of primary-care and cardiology patients found that people who received genome sequencing results showed the same rates of anxiety and depression as those in the control group, with no meaningful differences at any follow-up point.¹⁹

Even incidental findings, results about conditions you weren’t specifically testing for, tend not to cause lasting distress. A study following parents who received incidental findings from their child’s genome sequencing found that two years later, most reported little negative impact.²⁰ These studies involve people who received pre-test counseling and results disclosure from trained professionals, so the reassurance may not fully extend to someone getting a raw data dump from a consumer test with no context.

The Gray Zone of Uncertain Results

Not every genetic test result comes back as a clear positive or negative. Variants of uncertain significance, or VUSs, are genetic changes where the evidence is not yet strong enough to say whether the variant causes disease or is harmless. These ambiguous results are common in clinical testing and frustrate everyone involved: patients, doctors, and laboratories alike.²¹

VUS results are not supposed to change your medical care, but they often sit in the back of your mind. The good news is that as more genetic data accumulates, many VUSs get reclassified over time. A study of reclassified VUS results in breast, ovarian, and colorectal cancer genes found that about 11% of reclassified variants led to clinically actionable findings, and roughly 5% ended up changing patients’ clinical management.²² This means VUS results are worth following up on periodically, but acting on them prematurely, by pursuing aggressive screening or surgery, is usually a mistake.

Polygenic Risk Scores and Their Limits

Polygenic risk scores are a newer kind of genetic assessment. Instead of looking for a single high-impact mutation, they combine the small effects of thousands of common genetic variants to estimate your overall risk for conditions like heart disease, diabetes, or certain cancers. In theory, this could identify people at elevated risk who would not have been flagged by family history or traditional screening.

In practice, polygenic risk scores have a serious equity problem. The vast majority of the genetic studies used to build these scores drew their participants from people of European descent, and the scores work best in that population. Accuracy drops as a person’s genetic ancestry diverges from the training data. Research using a large, diverse biobank showed that accuracy decreased along a continuous gradient of genetic distance, and that individuals in the most distant group had about 14% lower accuracy than those closest to the training population.²³ The concern is that deploying these scores in clinical practice right now would systematically benefit people of European descent while providing less useful, potentially misleading results for everyone else.²⁴

Polygenic risk scores are an active area of research with real promise, but they are not yet ready for routine clinical use in diverse populations. If you encounter one as part of a consumer test, treat it as a rough indicator rather than a precise measurement.

Legal Protections and Their Gaps

In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits employers and health insurers from discriminating based on genetic information. That sounds comprehensive, but GINA does not cover life insurance, long-term care insurance, or disability insurance.²⁵ This gap is not hypothetical. People who test positive for a hereditary condition can be denied life or long-term care coverage or charged higher premiums based on that result. Some states have enacted additional protections, but coverage is patchy.

If you’re considering genetic testing and also planning to apply for life or disability insurance, the timing matters. Applying for those policies before getting tested means the information does not exist yet and cannot be used against you. This is one of those practical considerations that rarely comes up in the enthusiasm around testing but can have real financial consequences. It’s worth discussing with a genetic counselor before proceeding.

When Your Results Affect Your Family

Genetic information is inherently shared. A result that reveals you carry a harmful mutation means your siblings, parents, and children may carry it too. This creates both an opportunity and a burden. The opportunity is cascade testing: once a mutation is identified in one person, relatives can be tested specifically for that variant, which is simpler and cheaper than starting from scratch. Among relatives contacted about cascade testing for hereditary breast and ovarian cancer, about 86% expressed interest, and 71% of those interested completed testing.²⁶

But getting from a positive result in one family member to tested relatives is not as smooth as it sounds. The barriers are a mix of practical and emotional: concern about genetic discrimination, fear of getting a positive result themselves, beliefs that the variant is not relevant to their own health, and complicated family dynamics that make communication difficult.²⁷ You may find yourself in the position of deciding how, when, and whether to share medical information with relatives who did not ask for it. There is no universally right answer to that, but going in prepared for the conversation is better than being caught off guard by it.

Genetic Counseling and Why It Matters

A consistent theme across most genetic testing research is that results are more useful and less distressing when they come with professional guidance. Genetic counselors help before testing by explaining what a test can and cannot tell you, and after testing by translating results into decisions. A systematic review of the impact of genetic counseling on risk perception found that the proportion of people who accurately estimated their own risk increased by about 25 percentage points after a counseling session. Before counseling, an average of 42% understood their risk correctly; after counseling, that rose to about 58%.²⁸

That still leaves a large portion of people who overestimate or underestimate their risk even after counseling, which speaks to how inherently difficult genetic risk is to internalize. But the improvement is meaningful, and the gap between counseled and uncounseled patients is likely larger still. If you’re pursuing any form of clinical genetic testing, investing in counseling, whether or not your insurance covers it, is one of the best things you can do to make sure the results actually help you rather than leaving you more confused than you started.

Genomic Newborn Screening

One of the fastest-moving frontiers in genetic testing is its application to newborn screening. Conventional newborn screening uses biochemical tests on a heel-prick blood sample to detect metabolic conditions, and it has been one of the great public health success stories. The question now is whether adding genomic sequencing to that process can catch more conditions earlier. A proof-of-concept study found that genome sequencing could identify newborns with conditions that would otherwise go undetected until symptoms appeared, and that some of those children received changes in their medical management as young children because of the information.²⁹ Newborn screening programs using genomic approaches have shown sensitivity above 94% for detecting metabolic disorders before symptoms begin.³⁰

This is still largely in the pilot-program stage, and there are unresolved questions about how to handle the volume of uncertain results in apparently healthy babies, who pays for confirmatory testing, and whether parents can meaningfully consent to something this broad in the hectic first days after birth. But the trajectory is toward more genomic information at birth, not less, and future parents will increasingly face the question of whether to opt in.